Results 51 to 60 of about 19,378,005 (296)

The T cell receptor/CD3 complex is composed of at least two autonomous transduction modules [PDF]

open access: yes, 1992
Recent studies have demonstrated that the CD3-ζ subunit of the T cell antigen receptor (TCR) complex is involved in signal transduction. However, the function of the remaining invariant subunits, CD3-γ, -δ, and , is still poorly understood.
Wegener, Anne-Marie K.   +19 more
core   +1 more source

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

open access: yesHaematologica, 2016
Adoptive transfer of chimeric antigen receptor-transduced T cells is a promising strategy for cancer immunotherapy. The CD38 molecule, with its high expression on multiple myeloma cells, appears a suitable target for antibody therapy.
Esther Drent   +13 more
doaj   +1 more source

Therapeutic applications of engineered chimeric antigen receptors-T cell for cancer therapy

open access: yesBeni-Suef University Journal of Basic and Applied Sciences, 2022
Background Findings of new targeted treatments with adequate safety evaluations are essential for better cancer cures and mortality rates. Immunotherapy holds promise for patients with relapsed disease, with the ability to elicit long-term remissions ...
Amina Hussain
doaj   +1 more source

Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma

open access: yesCancers, 2023
Glioblastoma (GBM), the most common primary brain tumor in adults, is characterized by low survival rates and a grim prognosis. Current treatment modalities, including extensive surgical resection, chemotherapy, and radiation therapy, often yield limited success due to the brain’s sensitivity, leading to significant side effects.
Ma, Kun, Hu, Ping
openaire   +2 more sources

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

open access: yesFEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors

open access: yesNature Communications
The efficacy of Chimeric Antigen Receptor T cells against solid tumors is limited by immunosuppressive factors in the tumor microenvironment including adenosine, which suppresses Chimeric Antigen Receptor T cells through activation of the A2A receptor ...
Kevin Sek   +35 more
doaj   +1 more source

Antibody-conjugated lipid nanoparticles for in vivo CAR-T cell engineering: From concept to clinical translation

open access: yesNano Biomedicine and Engineering
Chimeric antigen receptor T cell therapy represents a transformative advancement in immunotherapy, wherein engineered T cells target tumor antigens, achieving high response rates in hematological malignancies.
Zhitong Guo, Mengjie Zhang, Yuanyu Huang
doaj   +1 more source

Chimeric antigen receptor T cell therapy for multiple myeloma

open access: yesInflammation and Regeneration, 2019
Chimeric antigen receptor (CAR) T cell therapy is a new cancer immunotherapy targeting cancer-specific cell surface antigen. CD19-CAR T cells have been already shown to be very effective to B cell leukemia/lymphoma.
Kana Hasegawa, Naoki Hosen
doaj   +1 more source

Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias [PDF]

open access: yesJournal of Immunotherapy and Precision Oncology, 2020
In recent years, cancer treatment has evolved, and new therapies have been introduced with significant improvement in prognosis. The immunotherapies stand out owing to their efficacy and remission rate. Chimeric antigen receptor (CAR) T-cell therapy is a
Cesar Clavijo Simbaqueba   +9 more
doaj   +1 more source

Chimeric antigen receptor T-cell therapy for ALL [PDF]

open access: yesHematology, 2014
Abstract Relapsed and refractory leukemias pose substantial challenges in both children and adults, with very little progress being made in more than a decade. Targeted immunotherapy using chimeric antigen receptor (CAR)-modified T cells has emerged as a potent therapy with an innovative mechanism.
Shannon L, Maude   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy